Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.
Tatenhorst, Lars
Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease. [electronic resource] - Journal of neuropathology and experimental neurology Aug 2014 - 770-9 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1554-6578
10.1097/NEN.0000000000000095 doi
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine--analogs & derivatives
Adrenergic Agents--toxicity
Animals
Apomorphine
Corpus Striatum--drug effects
Disease Models, Animal
Dopamine--metabolism
Dopamine Plasma Membrane Transport Proteins--metabolism
Male
Mice
Mice, Inbred C57BL
Motor Activity--drug effects
Muscle Strength--drug effects
Oxidopamine--toxicity
Parkinson Disease--drug therapy
Protein Kinase Inhibitors--therapeutic use
Substantia Nigra--pathology
Time Factors
Tyrosine 3-Monooxygenase--metabolism
Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease. [electronic resource] - Journal of neuropathology and experimental neurology Aug 2014 - 770-9 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
1554-6578
10.1097/NEN.0000000000000095 doi
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine--analogs & derivatives
Adrenergic Agents--toxicity
Animals
Apomorphine
Corpus Striatum--drug effects
Disease Models, Animal
Dopamine--metabolism
Dopamine Plasma Membrane Transport Proteins--metabolism
Male
Mice
Mice, Inbred C57BL
Motor Activity--drug effects
Muscle Strength--drug effects
Oxidopamine--toxicity
Parkinson Disease--drug therapy
Protein Kinase Inhibitors--therapeutic use
Substantia Nigra--pathology
Time Factors
Tyrosine 3-Monooxygenase--metabolism